Anti-EGFR Therapy in Right-Sided Metastatic Colorectal Cancer: Right or Wrong?
Authors: Benjamin A. Weinberg
Journal: Journal of the National Comprehensive Cancer Network (2018)

Colorectal cancer (CRC) is the second leading cause of cancer-related death in the United States after lung cancer, and American Cancer Society sources estimate that more than 50,000 Americans will die of CRC this year alone. 1In addition to chemotherapy, biologic agents are an important component of the arsenal against metastatic CRC (mCRC).Use of cetuximab and panitumumab, which are monoclonal antibodies targeting the epidermal growth factor receptor (EGFR), has evolved substantially over the past 2 decades. 2 Immunohistochemical evidence of EGFR-positivity in tumors was initially thought to be an appropriate therapeutic biomarker, but this EGFR expression was not predictive of response to cetuximab, 2 and the response rate for patients with EGFR-positive chemorefractory mCRC treated with cetuximab was only 8%. 3 Further work demonstrated that cetuximab treatment outcomes were worse for patients with tumor mutations in KRAS exon 2 than for their wild-type counterparts. 4However, KRAS exon 2 mutations are only part of the picture; thus, patients with mutations in KRAS exons 3-4 and NRAS exons 2-4 also do not benefit from anti-EGFR therapy. 5,6Patients with BRAF V600E mutations likewise do not benefit from EGFR inhibitors unless combined with irinotecan and BRAF-targeted therapies.More recently, tumor sidedness has emerged as another predictive biomarker for response to cetuximab and panitumumab in the RAS and BRAF wild-type population.Patients with mCRC and right-sided primary tumors (cecum, ascending and proximal transverse colon) have inferior overall survival compared with patients with mCRC and left-sided primaries (distal transverse, descending, and sigmoid colon and rectum). 7oreover, patients with right-sided primaries do not benefit from cetuximab in the firstline setting, whereas patients with left-sided primaries clearly benefit. 8n the CALGB/SWOG 80405 study of first-line chemotherapy plus cetuximab versus chemotherapy plus bevacizumab in patients with KRAS exon 2 wild-type mCRC, the longest overall survival was seen in the study arm that included patients with leftsided tumors treated with cetuximab (36.0 months), followed by the left-sided tumors treated with bevacizumab arm (31.4 months), followed by the right-sided tumors treated with bevacizumab arm (24.2 months), and finally the right-sided tumors treated with cetuximab arm (16.7 months). 8Although cetuximab led to worse outcomes in patients with right-sided tumors regardless of KRAS status, it can be suggested that patients with RAS and BRAF wild-type left-sided primary tumors should receive anti-EGFR therapy in the first line.Perhaps the treatment sequence is important in this latter case, and EGFR therapy upfront improves response to future lines of therapy.These findings raise some inevitable questions: can we ever use anti-EGFR drugs in the treatment of patients with right-sided mCRC, particularly in those with RAS and BRAF wild-type tumors, as a later line of therapy, and what other biomarkers can we use to inform this decision?In this issue of JNCCN, Kratz et al attempt to answer this question by looking at tumor bulk using 3.5 cm as a cutoff.In a small retrospective analysis in the late-line setting, these authors show that anti-EGFR therapies work best in nonbulky (small) tumors, especially when the tumors are on the left side.Most importantly, nonbulky right-sided mCRCs respond to anti-EGFR therapy, but only with the addition of chemotherapy.Small sample numbers make drawing definitive conclusions difficult, but these results suggest that anti-EGFR monotherapy should be avoided in patients with nonbulky rightsided mCRC and that anti-EGFR therapy, whether alone or in combination, should be avoided altogether in patients with bulky right-sided mCRC.The authors reasonably